Clinical and molecular prognostic factors in renal cell carcinoma: What we know so far

Hematology/Oncology Clinics of North America

Volumn 25, Issue 4, 2011, Pages 871-891

  Tang, Patricia A ^a   Vickers, Michael M ^a   Heng, Daniel Y C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Biomarkers; Predictive factors; Prognostic factors; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL CELL ADHESION MOLECULE; EVEROLIMUS; GELSOLIN; GENE PRODUCT; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TEMSIROLIMUS; THYMIDYLATE SYNTHASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN A; VIMENTIN; VON HIPPEL LINDAU PROTEIN;

ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960374629     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.04.003     Document Type: Review

References (115)

1. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 1. CD001425.
2. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655.
3. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688.
4. Klapper J.A., Downey S.G., Smith F.O., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113:293.
5. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125.
7. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103.
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115.
9. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137.
10. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061.
11. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271.
12. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256.
13. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449.
14. Dancey J.E., Dobbin K.K., Groshen S., et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010, 16:1745.
15. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003, 98:2566.
16. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794.
17. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832.
18. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289.
19. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530.
20. Patil S., Figlin R.A., Hutson T.E., et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011, 22:295.
21. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649.
22. Motzer R.J., Bukowski R.M., Figlin R.A., et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008, 113:1552.
23. Royston P., Reitz M., Atzpodien J. An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer 2006, 94:1785.
24. Jeppesen A.N., Jensen H.K., Donskov F., et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010, 102:867.
25. Schutz F.A., Xie W., Heng D.Y., et al. The effect of low serum sodium on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration. J Clin Oncol 2011, 29. [abstract: 322].
26. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543.
27. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988, 48:7310.
28. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002, 13:1460.
29. Atzpodien J., Royston P., Wandert T., et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003, 88:348.
30. Ljungberg B., Grankvist K., Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76:1435.
31. Ljungberg B., Landberg G., Alamdari F.I. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000, 34:246.
32. Suppiah R., Shaheen P.E., Elson P., et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006, 107:1793.
33. Hollen C.W., Henthorn J., Koziol J.A., et al. Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma 1992, 8:235.
34. Mohle R., Green D., Moore M.A., et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997, 94:663.
35. O'Byrne K.J., Dobbs N., Propper D., et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999, 353:1494.
36. Ficarra V., Martignoni G., Lohse C., et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 2006, 175:1235.
37. Fujii Y., Saito K., Iimura Y., et al. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol 2008, 180:1290.
38. Heng D.Y., Chi K.N., Murray N., et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009, 115:776.
39. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89.
40. Seizinger B.R., Rouleau G.A., Ozelius L.J., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268.
41. Brauch H., Weirich G., Brieger J., et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 1942, 60:2000.
42. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85.
43. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700.
44. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34:58.
45. Schraml P., Struckmann K., Hatz F., et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196:186.
46. Shuin T., Kondo K., Torigoe S., et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852.
47. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13:680s.
48. Baldewijns M.M., van Vlodrop I.J., Smits K.M., et al. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cell Oncol 2009, 31:371.
49. Smits K.M., Schouten L.J., van Dijk B.A., et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008, 14:782.
50. Patard J.J., Fergelot P., Karakiewicz P.I., et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008, 123:395.
51. Yao M., Yoshida M., Kishida T., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569.
52. Kim J.H., Jung C.W., Cho Y.H., et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005, 13:859.
53. Mandriota S.J., Turner K.J., Davies D.R., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459.
54. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860.
55. Gad S., Sultan-Amar V., Meric J., et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol 2007, 2:3.
56. Hutson T.E., Davis I.D., Machiels J.H., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26 [abstract: 5046].
57. Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379.
58. Lidgren A., Hedberg Y., Grankvist K., et al. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006, 50:1272.
59. Dorevic G., Matusan-Ilijas K., Babarovic E., et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009, 28:40.
60. Klatte T., Seligson D.B., Riggs S.B., et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388.
61. Patel P.H., Chadalavada R.S., Ishill N.M., et al. Hypoxia-inducible factor (HIF) 1 and 2 levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008, 26. [abstract: 5008].
62. Figlin R.A., de Souza P., McDermott D., et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009, 115:3651.
63. Jacobsen J., Rasmuson T., Grankvist K., et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343.
64. Negrier S., Perol D., Menetrier-Caux C., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004, 22:2371.
65. Negrier S., Chabaud S., Escudier B., et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007, 25. [abstract: 5044].
66. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312.
67. Escudier B., Ravaud A., Negrier S., et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 2008, 26. [abstract: 5025].
68. Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32.
69. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743.
70. Tran H.T., Liu Y., Lin Y., et al. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. J Clin Oncol 2010, 28. [abstract: 4522].
71. Kim J.J., Vaziri S.A., Elson P., et al. Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension and clinical outcome in metastatic clear cell RCC patients treated with sunitinib. J Clin Oncol 2010, 28. [abstract: 4629].
72. Kim J.J., Vaziri S.A., Elson P., et al. VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 2009, 27. [abstract: 5005].
73. Xu C., Ball H.A., Bing N., et al. Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma. J Clin Oncol 2011, 29. [abstract: 303].
74. Ivanov S., Liao S.Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905.
75. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802.
76. Leibovich B.C., Sheinin Y., Lohse C.M., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757.
77. Sandlund J., Oosterwijk E., Grankvist K., et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007, 100:556.
78. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714.
79. de Martino M., Klatte T., Seligson D.B., et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 2009, 182:728.
80. McDermott D.F., Ghebremichael M.S., Signoretti S., et al. The high-dose aldesleukin (HD IL-2) " SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010, 28. [abstract: 4514].
81. Choueiri T.K., Regan M.M., Rosenberg J.E., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106:772.
82. Pena C., Lathia C., Shan M., et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010, 16:4853.
83. Kondo K., Yao M., Kobayashi K., et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001, 91:219.
84. Turner K.J., Moore J.W., Jones A., et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002, 62:2957.
85. Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in Cancer Patients. Clin Cancer Res 2003, 9:2887.
86. Tanaka C., O'Reilly T., Kovarik J.M., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596.
87. Carreno B.M., Collins M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol 2003, 24:524.
88. Krambeck A.E., Thompson R.H., Dong H., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006, 103:10391.
89. Thompson R.H., Kuntz S.M., Leibovich B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381.
90. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004, 101:17174.
91. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630.
92. Kortylewski M., Kujawski M., Wang T., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314.
93. Ito N., Eto M., Nakamura E., et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 2007, 25:2785.
94. Matthaeus T., Schulze-Lohoff E., Ichimura T., et al. Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney. J Am Soc Nephrol 2001, 12:787A.
95. Tong Z., Wu X., Ovcharenko D., et al. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005, 391:441.
96. Bolignano D., Donato V., Lacquaniti A., et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010, 288:10.
97. Barresi V., Ieni A., Bolignano D., et al. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep 2010, 24:305.
98. Porta C., Paglino C., De Amici M., et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809.
99. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556.
100. Hoffmann N.E., Sheinin Y., Lohse C.M., et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112:1471.
101. Shirasaka T., Shimamato Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548.
102. Naito S., Eto M., Shinohara N., et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010, 28:5022.
103. Kosari F., Parker A.S., Kube D.M., et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005, 11:5128.
104. Rini B.I., Zhou M., Aydin H., et al. Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2010, 28. [abstract: 4501].
105. Takahashi M., Rhodes D.R., Furge K.A., et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001, 98:9754.
106. Vasselli J.R., Shih J.H., Iyengar S.R., et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 2003, 100:6958.
107. Zhao H., Ljungberg B., Grankvist K., et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006, 3:e13.
108. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817.
109. Dupuy A., Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99:147.
110. Bui M.H., Visapaa H., Seligson D., et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004, 171:2461.
111. Dudderidge T.J., Stoeber K., Loddo M., et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005, 11:2510.
112. Tollefson M.K., Thompson R.H., Sheinin Y., et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer 2007, 110:783.
113. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496.
114. Parker A.S., Leibovich B.C., Lohse C.M., et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009, 115:2092.
115. Justice A.C., Covinsky K.E., Berlin J.A. Assessing the generalizability of prognostic information. Ann Intern Med 1999, 130:515.